Results 201 to 210 of about 132,358 (267)

Mechanistic Understanding of Protein–MOF Integration Through Surfactant‐Driven Interfacial Design

open access: yesAdvanced Science, EarlyView.
This study reveals how surfactant‐driven interfacial design governs the assembly and stability of protein@MOF composites. Using lipid‐based nonionic surfactants, we modulate protein–MOF interactions to improve encapsulation efficiency, MOF crystallization, and catalytic performance.
Ehsan Rashidniyaghi   +4 more
wiley   +1 more source

Nonionic peptide amphiphiles and their supramolecular co-assemblies tune charge density and bioactivity.

open access: yesJ Mater Chem B
Lewis JA   +5 more
europepmc   +1 more source

Intrinsically Mitochondria‐Targeting Nanozyme via Coordination‐Assembly of Natural Quercetin for Cascade Antioxidant Therapy of Cerebral Ischemia‐Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
This study uncovers that quercetin naturally targets mitochondria. By coordinating quercetin with Fe3+, we engineer an ultrasmall cascade nanozyme (MCN) with superoxide dismutase‐catalase activities. MCN crosses the damaged blood–brain barrier, scavenges mitochondrial ROS, prevents mitochondrial DNA leakage, and blocks the cGAS‐STING pathway, thereby ...
Wenxuan Zheng   +14 more
wiley   +1 more source

Editorial: Innovations in biologically active nutrients extraction and delivery

open access: yesFrontiers in Nutrition
Ahmed A. Zaky   +3 more
doaj   +1 more source

Endobody: Genetically Encodable Nanobody‐CPP Chimeras for Degradation of Membrane and Extracellular Proteins

open access: yesAdvanced Science, EarlyView.
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou   +3 more
wiley   +1 more source

A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007). [PDF]

open access: yesPharmaceuticals (Basel)
Wang C   +10 more
europepmc   +1 more source

Machine Learning-Driven Drug Repurposing for KRAS G12C and KRAS G12D Inhibition. [PDF]

open access: yesACS Omega
Fuschi G   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy